Shares of Viking Therapeutics have sold off sharply as the market awaits updates on its drug candidates. The company is ...

Oral VK2735 Phase 2 trial is currently underway ... emphasizing ongoing dialogues with global peptide suppliers to secure ...

Early trials of VK2735 produced positive data that spurred ... that has been investing in peptide production scale-up for ...

Discover why VKTX's deep selloff offers a compelling opportunity with improved safety margins, promising GLP-1 candidates, ...

Viking's Q1 earnings show no revenue, increased R&D spending, and a substantial cash reserve, positioning it well for future ...

announced the completion of subject enrollment in its Phase 2 clinical trial of the oral tablet formulation of VK2735, the company’s dual agonist of the glucagon-like peptide 1 and glucose ...

CordenPharma provides large-scale peptide manufacturing for the Dual GLP-1/GIP Receptor Agonist drug substance of VK2735. CordenPharma provides fill-finish for the drug candidate's subcutaneous ...

Pfizer ends danuglipron development after liver safety issue, boosting shares of Viking, Eli Lilly, and Novo Nordisk amid ...

While the company has not yet launched a product, its VK2735 candidate -- a dual agonist targeting glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP ...